25
Participants
Start Date
December 14, 2022
Primary Completion Date
October 8, 2024
Study Completion Date
December 2, 2024
Placebo
Placebo-matching capsules was administered orally.
SPR720 500 mg
SPR720 500 mg (250 mg × 2 capsules) was administered orally.
SPR720 1000 mg
SPR720 500 mg (250 mg × 4 capsules) was administered orally.
Medical Facility, New Hyde Park
Medical Facility, Pittsburgh
Medical Facility, Washington D.C.
Medical Facility, Winston-Salem
Medical Facility, Chapel Hill
Medical Facility, Charleston
Medical facility, Atlanta
Medical Facility, Miami
Medical Facility, Loxahatchee Groves
Medical Facility, Tampa
Medical Facility, Sebring
Medical Facility, Birmingham
Medical Facility, Cleveland
Medical Facility, Iowa City
Medical Facility, Rochester
Medical Facility, Kansas City
Medical Facility, Denison
Medical Facility, Sherman
Medical Facility, Tyler
Medical Facility, Los Angeles
Medical Facility, Northridge
Medical Facility, Santa Clarita
Medical Facility, Newport Beach
Medical Facility, Fresno
Medical Facility, Portland
Medical Facility, Kissimmee
Medical Facility, New Bedford
Medical Facility, Lebanon
Lead Sponsor
Spero Therapeutics
INDUSTRY